[FG] Fani Melpomeni

Eigler, Christopher et al. (2024) ‘Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study’, Journal of Nuclear Medicine, 65, pp. 573–579. Available at: https://doi.org/10.2967/jnumed.123.266817.

Fricke, Julia et al. (2024) ‘First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([ 161 Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum’, European Journal of Nuclear Medicine and Molecular Imaging [Preprint]. Available at: https://doi.org/10.1007/s00259-024-06641-w.

Friebe, Liene et al. (2024) ‘Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis’, Journal of Nuclear Medicine, 65, pp. 228–235. Available at: https://doi.org/10.2967/jnumed.123.265894.

Neubauer, Moritz C. et al. (2024) ‘Early response monitoring during [ 177 Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study’, European Journal of Nuclear Medicine and Molecular Imaging, 51, pp. 1185–1193. Available at: https://doi.org/10.1007/s00259-023-06536-2.

Schürrle, Seval Beykan et al. (2024) ‘Dosimetry and pharmacokinetics of [ 177 Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours’, European Journal of Nuclear Medicine and Molecular Imaging [Preprint]. Available at: https://doi.org/10.1007/s00259-024-06682-1.

von Niederhäusern, P.A. et al. (2024) ‘Augmented reality for sentinel lymph node biopsy’, International Journal of Computer Assisted Radiology and Surgery, 19, pp. 171–180. Available at: https://doi.org/10.1007/s11548-023-03014-w.

Kraihammer M et al. (2023) ‘Improved quality control of [(177)Lu]Lu-PSMA I&T.’, EJNMMI radiopharmacy and chemistry, 8(1), p. 7. Available at: https://doi.org/10.1186/s41181-023-00191-6.

Fani, Melpomeni and Nicolas, Guillaume P. (2023) ‘⁶¹Cu-labeled radiotracers: Alternative or choice?’, Journal of Nuclear Medicine, 64, pp. 1855–1857. Available at: https://doi.org/10.2967/jnumed.123.266171.

Gaonkar, Raghuvir Haridas et al. (2023) ‘Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications’, Journal of Medicinal Chemistry, 66, pp. 8484–8497. Available at: https://doi.org/10.1021/acs.jmedchem.3c00131.

Grand-Guillaume, Joana et al. (2023) ‘CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (^123/131I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors’, Journal of Translational Medicine, 21. Available at: https://doi.org/10.1186/s12967-023-04466-z.

Imperiale, Alessio et al. (2023) ‘The Emergence of Somatostatin Antagonist–Based Theranostics: Paving the Road Toward Another Success?’, Journal of Nuclear Medicine, 64, pp. 682–684. Available at: https://doi.org/10.2967/jnumed.123.265406.

Karnam, Murali et al. (2023) ‘Qualitative and quantitative assessment of admittance controllers for hand-guiding surgical robots’, At-Automatisierungstechnik, 71, pp. 515–527. Available at: https://doi.org/10.1515/auto-2023-0063.

Millul, Jacopo et al. (2023) ‘Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides’, European Journal of Nuclear Medicine and Molecular Imaging, 50(10), pp. 3050–3061. Available at: https://doi.org/10.1007/s00259-023-06272-7.

Novak, Doroteja et al. (2023) ‘Development of the ^99mTc-Labelled SST<inf>2</inf> Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study’, Pharmaceutics, 15. Available at: https://doi.org/10.3390/pharmaceutics15030885.

Opalinska, Marta et al. (2023) ‘Comparison of 99mTc radiolabeled somatostatin antagonist with [⁶⁸ Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor’, European Journal of Nuclear Medicine and Molecular Imaging, 50, pp. 4110–4111. Available at: https://doi.org/10.1007/s00259-023-06335-9.

Wild, Damian and Fani, Melpomeni (2023) ‘Case Study #6: [177Lu]Lu-DOTA-JR11: A Somatostatin Receptor Subtype 2 Antagonist for Radiopharmaceutical Therapy’, in Radiopharmaceutical Therapy. Cham: Springer International Publishing (Radiopharmaceutical Therapy), pp. 335–348. Available at: https://doi.org/10.1007/978-3-031-39005-0_16.

Wild, Damian et al. (2023) ‘A phase I/II study of the safety and efficacy of [ 177 Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours’, European Journal of Nuclear Medicine and Molecular Imaging, 51, pp. 183–195. Available at: https://doi.org/10.1007/s00259-023-06383-1.

Varum F et al. (2022) ‘Targeted colonic release formulations of mesalazine - A clinical pharmaco-scintigraphic proof-of-concept study in healthy subjects and patients with mildly active ulcerative colitis.’, International journal of pharmaceutics, 625, p. 122055. Available at: https://doi.org/10.1016/j.ijpharm.2022.122055.

Fani, Melpomeni et al. (2022) ‘Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals’, Cancers, 14(5). Available at: https://doi.org/10.3390/cancers14051172.

Theiler D. et al. (2021) ‘Safety and efficacy of peptide-receptor radionuclide therapy in elderly neuroendocrine tumor patients’, Cancers, 13(24). Available at: https://doi.org/10.3390/cancers13246290.

Hayes AR et al. (2021) ‘Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy.’, The Journal of clinical endocrinology and metabolism, 106(12), pp. e4903–e4916. Available at: https://doi.org/10.1210/clinem/dgab588.

Refardt J et al. (2021) ‘Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges.’, Reviews in endocrine & metabolic disorders, 22(3), pp. 581–594. Available at: https://doi.org/10.1007/s11154-020-09552-x.

Wild D et al. (2021) ‘Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 62(Suppl 2), pp. 44S–50S. Available at: https://doi.org/10.2967/jnumed.120.246009.

Mansi R and Fani M (2021) ‘Radiolabeled Peptides for Cancer Imaging and Therapy: From Bench-to-Bedside.’, Chimia, 75(6), pp. 500–504. Available at: https://doi.org/10.2533/chimia.2021.500.

Gaonkar RH et al. (2021) ‘SPECT Imaging of SST2-Expressing Tumors with (99m)Tc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers.’, Pharmaceuticals (Basel, Switzerland), 14(4). Available at: https://doi.org/10.3390/ph14040300.

Ambrosini V et al. (2021) ‘Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.’, European journal of cancer (Oxford, England : 1990), 146, pp. 56–73. Available at: https://doi.org/10.1016/j.ejca.2021.01.008.

Herth MM et al. (2021) ‘On the consensus nomenclature rules for radiopharmaceutical chemistry - Reconsideration of radiochemical conversion.’, 93. Available at: https://doi.org/10.1016/j.nucmedbio.2020.11.003.

Mansi, Rosalba et al. (2021) ‘Distinct in vitro binding profile of the somatostatin receptor subtype 2 antagonist [¹⁷⁷ lu]lu-ops201 compared to the agonist [¹⁷⁷ lu]lu-dota-tate’, Pharmaceuticals, 14. Available at: https://doi.org/10.3390/ph14121265.

Fani M et al. (2020) ‘Selection of the First (99m)Tc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation-Preclinical Assessment of Two Optimized Candidates.’, Pharmaceuticals (Basel, Switzerland), 14(1). Available at: https://doi.org/10.3390/ph14010019.

Mansi R et al. (2020) ‘Evaluation of a New (177)Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5.’, Molecules (Basel, Switzerland), 25(18). Available at: https://doi.org/10.3390/molecules25184155.

Antwi K et al. (2020) ‘Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging.’, Clinical nuclear medicine, 45(9), pp. e386–e392. Available at: https://doi.org/10.1097/rlu.0000000000003124.

Mansi R et al. (2020) ‘A new (68)Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting.’, EJNMMI research, 10(1), p. 90. Available at: https://doi.org/10.1186/s13550-020-00677-3.

Christ E et al. (2020) ‘Innovative imaging of insulinoma: the end of sampling? A review.’, Endocrine-related cancer, 27(4), pp. R79–R92. Available at: https://doi.org/10.1530/erc-19-0476.

Rottenburger C et al. (2020) ‘Cholecystokinin 2 Receptor Agonist (177)Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 61(4), pp. 520–526. Available at: https://doi.org/10.2967/jnumed.119.233031.

Coto-Llerena, Mairene et al. (2020) ‘High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes’, Frontiers in Oncology, 10, p. 979. Available at: https://doi.org/10.3389/fonc.2020.00979.

Antwi K et al. (2019) ‘68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1.’, The Journal of clinical endocrinology and metabolism, 104(12), pp. 5843–5852. Available at: https://doi.org/10.1210/jc.2018-02754.

von Niederhäusern PA et al. (2019) ‘Augmenting camera images with gamma detector data: A novel approach to support sentinel lymph node biopsy’, EJNMMI Physics, 6(1), p. 10. Available at: https://doi.org/10.1186/s40658-019-0245-z.

Zamboglou C et al. (2019) ‘Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference.’, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 141, pp. 208–213. Available at: https://doi.org/10.1016/j.radonc.2019.07.002.

Mansi R. and Fani M. (2019) ‘Design and development of the theranostic pair 177Lu-OPS201/68Ga-OPS202 for targeting somatostatin receptor expressing tumors’, Journal of Labelled Compounds and Radiopharmaceuticals, 62(10), pp. 635–645. Available at: https://doi.org/10.1002/jlcr.3755.

Antwi K et al. (2019) ‘Volume Replacement Fluid Demarks Benign Insulinoma With 68Ga-DOTA-Exendin-4 PET/CT.’, Clinical nuclear medicine, 44(5), pp. e347–e348. Available at: https://doi.org/10.1097/rlu.0000000000002522.

Antwi K et al. (2019) ‘Molecular imaging for neuroendocrine tumours.’, Swiss medical weekly, 149, p. w20017. Available at: https://doi.org/10.4414/smw.2019.20017.

Beykan S et al. (2019) ‘In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry.’, Contrast media & molecular imaging, 2019, p. 6438196. Available at: https://doi.org/10.1155/2019/6438196.

Sauter AW et al. (2019) ‘Targeting of the cholecystokinin-2 receptor with the minigastrin analog 177 Lu-DOTA-PP-F11N: Does the use of protease inhibitors further improve in vivo distribution?’, Journal of Nuclear Medicine. 12.07.2018, 60(3), pp. 393–399. Available at: https://doi.org/10.2967/jnumed.118.207845.

von Niederhausern P.A. et al. (2019) ‘Gamma Source Location Learning from Synthetic Multi-pinhole Collimator Data’. Springer Science and Business Media Deutschland GmbH, pp. 205–214. Available at: https://doi.org/10.1007/978-3-030-33843-5_19.

Nicolas GP et al. (2018) ‘New Developments in Peptide Receptor Radionuclide Therapy.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine [Preprint]. Available at: https://doi.org/10.2967/jnumed.118.213496.

Antwi K et al. (2018) ‘Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study.’, European journal of nuclear medicine and molecular imaging, 45(13), pp. 2318–2327. Available at: https://doi.org/10.1007/s00259-018-4101-5.

Nicolas GP et al. (2018) ‘Safety, Biodistribution, and Radiation Dosimetry of (68)Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 59(6), pp. 909–914. Available at: https://doi.org/10.2967/jnumed.117.199737.

Nicolas GP et al. (2018) ‘Sensitivity Comparison of (68)Ga-OPS202 and (68)Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 59(6), pp. 915–921. Available at: https://doi.org/10.2967/jnumed.117.199760.

Nock B.A. et al. (2018) ‘New Gastrin Releasing Peptide Receptor-Directed [ 99m Tc]Demobesin 1 Mimics: Synthesis and Comparative Evaluation’, Journal of Medicinal Chemistry, 61(7), pp. 3138–3150. Available at: https://doi.org/10.1021/acs.jmedchem.8b00177.

Nicolas GP, Wild D and Fani M (2018) ‘Reply: Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists.’, 59(3). Available at: https://doi.org/10.2967/jnumed.117.203703.

Abiraj, Keelara et al. (2018) ‘The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist’, EJNMMI research, 8, p. 75. Available at: https://doi.org/10.1186/s13550-018-0428-y.

Rylova SN et al. (2018) ‘The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model.’, PloS one. 18.04.2018, 13(4), p. e0195802. Available at: https://doi.org/10.1371/journal.pone.0195802.

Katona B.W. et al. (2017) ‘Efficacy of Peptide Receptor Radionuclide Therapy in a United States-Based Cohort of Metastatic Neuroendocrine Tumor Patients: Single-Institution Retrospective Analysis’, Pancreas, 46(9), pp. 1121–1126. Available at: https://doi.org/10.1097/mpa.0000000000000919.

Fani M, Nicolas GP and Wild D (2017) ‘Somatostatin Receptor Antagonists for Imaging and Therapy.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 58(Suppl 2), pp. 61S–66S. Available at: https://doi.org/10.2967/jnumed.116.186783.

Nicolas GP et al. (2017) ‘Biodistribution, Pharmacokinetics, and Dosimetry of (177)Lu-, (90)Y-, and (111)In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist (177)Lu-DOTATATE: The Mass Effect.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 58(9), pp. 1435–1441. Available at: https://doi.org/10.2967/jnumed.117.191684.

Fani M, Peitl PK and Velikyan I (2017) ‘Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.’, Pharmaceuticals (Basel, Switzerland), 10(1). Available at: https://doi.org/10.3390/ph10010030.

Fendler WP et al. (2017) ‘68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 58(2), pp. 307–311. Available at: https://doi.org/10.2967/jnumed.116.179192.

Melpomeni,Fani (2017) ‘Current and Future Radiopharmaceuticals in Neuroendocrine Tumor Imaging’, pp. 141–162. Available at: https://doi.org/10.1007/978-3-319-46038-3_7.

Seystahl K et al. (2016) ‘Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.’, Neuro-oncology, 18(11), pp. 1538–1547. Available at: https://doi.org/10.1093/neuonc/now060.

Baumann T et al. (2016) ‘Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.’, Best practice & research. Clinical endocrinology & metabolism, 30(1), pp. 45–57. Available at: https://doi.org/10.1016/j.beem.2016.01.003.

Nicolas, G. et al. (2016) ‘Somatostatin Receptor PET/CT with Radiolabelled Antagonist Is Twice as Effective as the Agonist for Detecting Liver Metastases: Results of a Phase 1/2 Study Comparing 68Ga-OPS202 with 68Ga-DOTATOC PET/CT in Gastroenteropancreatic NET Patients’. KARGER, 103.

Christ E et al. (2015) ‘Preoperative localization of adult nesidioblastosis using ⁶⁸Ga-DOTA-exendin-4-PET/CT.’, Endocrine, 50(3), pp. 821–3. Available at: https://doi.org/10.1007/s12020-015-0633-7.

Riff BP et al. (2015) ‘Peptide Receptor Radionuclide Therapy-Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors.’, Clinical nuclear medicine, 40(11), pp. 845–50. Available at: https://doi.org/10.1097/rlu.0000000000000935.

Bauman A et al. (2015) ‘Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 06.08.2015, 56(10), pp. 1569–74. Available at: https://doi.org/10.2967/jnumed.115.159186.

Antwi K et al. (2015) ‘Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 56(7), pp. 1075–8. Available at: https://doi.org/10.2967/jnumed.115.157768.

Wenning AS et al. (2015) ‘Preoperative Glucagon-like peptide-1 receptor imaging reduces surgical trauma and pancreatic tissue loss in insulinoma patients: a report of three cases.’, Patient safety in surgery, 9, p. 23. Available at: https://doi.org/10.1186/s13037-015-0064-7.

Christ,Emanuel et al. (2015) ‘Preoperative localization of adult nesidioblastosis using (68)Ga-DOTA-exendin-4-PET/CT.’, Endocrine, 50(3), pp. 821–3.

Fani,Melpomeni and Maecke,Helmut R. (2015) ‘Radiolabeled Somatostatin Receptor Antagonists’, in John Wiley & Sons Inc. (John Wiley & Sons Inc.), pp. 306–321.

Rylova SN et al. (2014) ‘Does imaging αvβ3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy?’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 02.10.2014, 55(11), pp. 1878–84. Available at: https://doi.org/10.2967/jnumed.114.137570.

Wild D et al. (2014) ‘Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 55(8), pp. 1248–52. Available at: https://doi.org/10.2967/jnumed.114.138834.

Cordier, Dominik et al. (2014) ‘Expression of different neurokinin-1 receptor (NK1R) isoforms in glioblastoma multiforme: potential implications for targeted therapy’, Cancer Biotherapy and Radiopharmaceuticals, 29(5), pp. 221–6. Available at: https://doi.org/10.1089/cbr.2013.1588.

Patra, Malay et al. (2014) ‘An octadentate bifunctional chelating agent for the development of stable zirconium-89 based molecular imaging probes’, Chemical Communications, 50(78), pp. 11523–11525. Available at: https://doi.org/10.1039/c4cc05558f.

Mindt,T.L. et al. (2014) ‘Octacoordinating Zirconium Ligands and their Use in Diagnostic Imaging and Therapy’, -.

Bouziotis P et al. (2013) ‘Radiochemical and radiobiological assessment of a pyridyl-S-cysteine functionalized bombesin derivative labeled with the (99m)Tc(CO)3(+) core.’, Bioorganic & medicinal chemistry. 12.08.2013, 21(21), pp. 6699–707. Available at: https://doi.org/10.1016/j.bmc.2013.08.010.

Christ E et al. (2013) ‘Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.’, The lancet. Diabetes & endocrinology, 1(2), pp. 115–22. Available at: https://doi.org/10.1016/s2213-8587(13)70049-4.

Valverde IE et al. (2013) ‘1,2,3-Triazoles as amide bond mimics: triazole scan yields protease-resistant peptidomimetics for tumor targeting.’, Angewandte Chemie (International ed. in English). 05.07.2013, 52(34), pp. 8957–60. Available at: https://doi.org/10.1002/anie.201303108.

Leonhardt F et al. (2013) ‘Inflammatory neovascularization during graft-versus-host disease is regulated by αv integrin and miR-100.’, Blood. 17.01.2013, 121(17), pp. 3307–18. Available at: https://doi.org/10.1182/blood-2012-07-442665.

Valverde,Ibai E. et al. (2013) ‘1,2,3-Triazole als Mimetika der Amid-Bindung: Ein Triazol-Scan führt zu Protease-resistenten Peptidmimetika für das Tumor-Targeting’, Angewandte Chemie, 125(4), pp. 9126–9129.

Wang X et al. (2012) ‘Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy.’, European journal of nuclear medicine and molecular imaging. 29.08.2012, 39(12), pp. 1876–85. Available at: https://doi.org/10.1007/s00259-012-2231-8.

Kluba CA et al. (2012) ‘Dual-targeting conjugates designed to improve the efficacy of radiolabeled peptides.’, Organic & biomolecular chemistry, 10(37), pp. 7594–602. Available at: https://doi.org/10.1039/c2ob26127h.

Fani M et al. (2012) ‘Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 31.07.2012, 53(9), pp. 1481–9. Available at: https://doi.org/10.2967/jnumed.112.102764.

Giovacchini G, Nicolas G and Forrer F (2012) ‘Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors.’, Anti-cancer agents in medicinal chemistry, 12(5), pp. 526–42. Available at: https://doi.org/10.2174/187152012800617803.

Fani M et al. (2012) ‘In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.’, Molecular pharmaceutics. 23.04.2012, 9(5), pp. 1136–45. Available at: https://doi.org/10.1021/mp200418f.

Psimadas D et al. (2012) ‘Synthesis and comparative assessment of a labeled RGD peptide bearing two different ⁹⁹mTc-tricarbonyl chelators for potential use as targeted radiopharmaceutical.’, Bioorganic & medicinal chemistry. 03.03.2012, 20(8), pp. 2549–57. Available at: https://doi.org/10.1016/j.bmc.2012.02.051.

Wiewiorski M et al. (2012) ‘Revision of failed osteochondral autologous transplantation procedure for chronic talus osteochondral lesion with iliac crest graft and autologous matrix-induced chondrogenesis: a case report.’, Foot & ankle specialist, 5(2), pp. 115–20. Available at: https://doi.org/10.1177/1938640011434046.

Fani, Melpomeni and Maecke, Helmut R. (2012) ‘Radiopharmaceutical development of radiolabelled peptides’, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. WOS.SCI, 39, pp. 11–30. Available at: https://doi.org/10.1007/s00259-011-2001-z.

Fani M, Maecke HR and Okarvi SM (2012) ‘Radiolabeled peptides: valuable tools for the detection and treatment of cancer.’, Theranostics. 16.05.2012, 2(5), pp. 481–501. Available at: https://doi.org/10.7150/thno.4024.

Ivanova K et al. (2012) ‘Acute toxoplasmosis mimicking melanoma metastases: review of conditions causing false-positive results on (18)F-FDG PET/CT.’, Dermatology (Basel, Switzerland), 225(4), pp. 349–53. Available at: https://doi.org/10.1159/000346333.

Cescato R et al. (2011) ‘Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 08.11.2011, 52(12), pp. 1886–90. Available at: https://doi.org/10.2967/jnumed.111.095778.

Wild D et al. (2011) ‘First clinical evidence that imaging with somatostatin receptor antagonists is feasible.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 18.08.2011, 52(9), pp. 1412–7. Available at: https://doi.org/10.2967/jnumed.111.088922.

Bauman, A. et al. (2011) ‘Synthesis, labelling and evaluation of hydantoin-substituted indole carboxylic acids as potential ligands for positron emission tomography imaging of the glycine binding site of the N-methyl-D-aspartate receptor’, JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. WOS.IC, 54, pp. 645–656. Available at: https://doi.org/10.1002/jlcr.1901.

Dumont RA et al. (2011) ‘Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of α(ν)β(3) integrin expression and facile radiosynthesis.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 15.07.2011, 52(8), pp. 1276–84. Available at: https://doi.org/10.2967/jnumed.111.087700.

Fani M et al. (2011) ‘PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 16.06.2011, 52(7), pp. 1110–8. Available at: https://doi.org/10.2967/jnumed.111.087999.

Knetsch PA et al. (2011) ‘[68Ga]NODAGA-RGD for imaging αvβ3 integrin expression.’, European journal of nuclear medicine and molecular imaging. 13.04.2011, 38(7), pp. 1303–12. Available at: https://doi.org/10.1007/s00259-011-1778-0.

Abiraj, Keelara et al. (2011) ‘Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors’, Journal of nuclear medicine, 52(12), pp. 1970–8. Available at: https://doi.org/10.2967/jnumed.111.094375.

Ambrosini, Valentina et al. (2011) ‘Radiopeptide imaging and therapy in Europe’, Journal of nuclear medicine, 52 Suppl 2, pp. 42S–55S. Available at: https://doi.org/10.2967/jnumed.110.085753.

Arrowsmith, Rory L et al. (2011) ‘Fluorescent gallium and indium bis(thiosemicarbazonates) and their radiolabelled analogues : synthesis, structures and cellular confocal fluorescence imaging investigations’, Dalton transactions, 40(23), pp. 6238–52. Available at: https://doi.org/10.1039/c1dt10126a.

Fani M et al. (2011) ‘Development of new folate-based PET radiotracers: preclinical evaluation of ⁶⁸Ga-DOTA-folate conjugates.’, European journal of nuclear medicine and molecular imaging, 38(1), pp. 108–19. Available at: https://doi.org/10.1007/s00259-010-1597-8.

Giovacchini, Giampiero et al. (2011) ‘Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy’, European journal of nuclear medicine and molecular imaging, 38(9), pp. 1675–82. Available at: https://doi.org/10.1007/s00259-011-1826-9.

Nicolas, Guillaume et al. (2011) ‘Targeted radiotherapy with radiolabeled somatostatin analogs’, Endocrinology and metabolism clinics of North America, 40(1), pp. 187–204, ix–x. Available at: https://doi.org/10.1016/j.ecl.2010.12.006.